NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Selecxine

Selecxine

Private
PohangHealthcare & Life Scienceshttps://selecxine.com/

Last Round

Series B

Mar 22, 2022

Total Funding Raised

$49.75M

Company Overview

Selecxine is a biopharmaceutical company that develops anti-cancer immunotherapeutics using its proprietary antibody discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyantibody-cytokine conjugateantibody discoverybiopharmacancer immunotherapydrug discoveryphage displayepitope mappingcell-based screeningprecision medicinebiotechclinical-stage biotechantibody engineeringCDMOcontract development and manufacturing organization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Selecxine Comparables

Compare Selecxine with similar companies based on industry and business-model similarity.

Selecxine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Asher Biotherapeutics
84%
Synthekine
82%
Anaveon
81%

Selecxine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 22, 2022
Series AMay 7, 2020

Key People

Founding team and executive leadership

GilTae Wie

COO CFO

Executive Team

Selecxine Investors

Notable investors and investment history

Selecxine investors
InvestorRounds
Hanwha Investment & SecuritiesSeries A, Series B
iM Investment PartnersSeries B
KCLAVIS InvestmentSeries B
UTC InvestmentSeries B
Hyundai Venture Investment Corp.Series B
Medici InvestmentSeries B
K-Run VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 29, 2022

    $27M round led by Hanwha Investment & Securities and Medytox Venture Investment.

  • May 7, 2020

    $11M round with participation from Hanwha Investment & Securities.

Selecxine Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Selecxine Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Selecxine's valuation, stock price, and market status.

Firmographic Details

HeadquartersPohang
Employee Range9
Year Founded2018
Last FundingMar 22, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.